Patient-Focused Drug Development: US FDA 'Needs To Be Brave,' Tell Sponsors What Works Best
Executive Summary
At public workshop, FDA says it will be flexible on clinical outcome assessments but stakeholders want agency to specify no-no's; digital health technology is appropriate to get more accurate endpoints, agency says.